M28 Capital Management’s Silence Therapeutics SLN Stock Holding History

M28 Capital Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$533K	Sell	101,203 -83,897	-45%	-$462K	0.99%	8
2025 Q4	$1.13M	Hold	185,100	–	–	0.82%	8
2025 Q3	$961K	Hold	185,100	–	–	1.41%	8
2025 Q2	$1.07M	Hold	185,100	–	–	1.83%	7
2025 Q1	$522K	Hold	185,100	–	–	0.72%	11
2024 Q4	$1.27M	Hold	185,100	–	–	1.25%	10
2024 Q3	$3.37M	Hold	185,100	–	–	3.7%	7
2024 Q2	$3.52M	Sell	185,100 -114,300	-38%	-$2.43M	4.56%	6
2024 Q1	$6.47M	Sell	299,400 -64,400	-18%	-$1.4M	4.78%	5
2023 Q4	$6.32M	Hold	363,800	–	–	5.24%	4
2023 Q3	$3.57M	Hold	363,800	–	–	4.1%	5
2023 Q2	$2M	Buy	363,800 +217,900	+149%	+$1.31M	2.64%	11
2023 Q1	$905K	Hold	145,900	–	–	1.02%	13
2022 Q4	$2.22M	Buy	+145,900	New	+$1.91M	2.12%	11

Other funds holding SLN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

M28 Capital Management's SLN Position: Q1 2026 in Review

M28 Capital Management reduced its Silence Therapeutics (SLN) stake by 45% in Q1 2026, selling an estimated $462K and leaving 101,203 shares worth $533K. The position accounts for 0.99% of the portfolio, ranked #8.

M28 Capital Management first reported a position in SLN in Q4 2022 and has held it in 14 quarters since. The position peaked at $6.47M in Q1 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

M28 Capital Management held 101,203 shares of Silence Therapeutics worth $533K as of Q1 2026.
M28 Capital Management sold 83,897 Silence Therapeutics shares in Q1 2026, an estimated $462K.
Silence Therapeutics made up 0.99% of M28 Capital Management's portfolio in Q1 2026, its #8 holding.
M28 Capital Management first reported a position in Silence Therapeutics in Q4 2022 and has held it in 14 quarters since.
M28 Capital Management's Silence Therapeutics position peaked at $6.47M in Q1 2024.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on M28 Capital Management's 13F filing for Q1 2026, filed 14 May 2026.